Pluristem Therapeutics (NASDAQ: HSKA) and Heska (NASDAQ: HSKA) are both small pharmaceutical companies, but which are the superior companies? We will compare the two companies based on the strength of their earnings, profitability, recommendations from analysts, dividends, risk, valuation and institutional ownership.
Income and appreciation
This table compares the turnover, earnings per share and valuation of Pluristem Therapeutics and Heska.
|Gross income||Price / sales ratio||Net income||Profit per share||Price / profit ratio|
|Pluristem Therapeutics||$ 2.85 million||52.91||– $ 27.81 million||(0.32 $)||-4.25|
|Heska||$ 129.34 million||5.98||$ 9.95 million||$ 2.07||49.86|
Heska has higher income and income than Pluristem Therapeutics. Pluristem Therapeutics is trading at a lower price-earnings ratio than Heska, indicating that it is currently the more affordable of the two shares.
Risk and volatility
Pluristem Therapeutics has a beta of 0.32, which means that the share price is 68% less volatile than the S & P 500. In comparison, Heska has a beta of 0.76, which means that the share price is 24% less volatile than the price. S & P 500.
This is a summary of recent valuations and target prices for Pluristem Therapeutics and Heska, as reported by MarketBeat.
|Sales reviews||Keep ratings||Buy ratings||Strong sales figures||Review score|
Pluristem Therapeutics currently has a consensus target of $ 4.13, indicating a potential benefit of 203.31%. Heska has a target price target of $ 107.50, indicating a potential increase rate of 4.16%. Given the stronger consensus of Pluristem Therapeutics and a higher likely positive benefit, equity research analysts are convinced that Pluristem Therapeutics is more beneficial than Heska.
Insider & institutional property
4.9% of Pluristem Therapeutics shares are held by institutional investors. By comparison, 89.6% of Heska's shares are held by institutional investors. 7.2% of Pluristem Therapeutics shares are owned by insiders of companies. By comparison, 15.9% of Heska shares are owned by insiders of companies. Strong institutional ownership is an indication that hedge funds, large money managers and capital providers think that a share is ready for long-term growth.
This table compares the net margins of Pluristem Therapeutics and Heska, the return on equity and the return on assets.
|Net margins||Return on equity||Return on assets|
|Pluristem Therapeutics||N / A||-77.44%||-61.88%|
Heska defeats Pluristem Therapeutics on 10 of the 13 factors that were compared between the two stocks.
About Pluristem Therapeutics
Pluristem Therapeutics, Inc. is a biotechnology company that is engaged in the provision of cell therapy. It develops products based on placenta for cell therapy for the treatment of multiple ischemic, inflammatory and hematological disorders. The company focuses on cell therapies for the treatment of diseases such as muscle damage, acute radiation syndrome, pulmonary arterial hypertension and others. The products include PLacental eXpanded, PLX-PAD and PLX-R18. The company was founded by Doron Shorrer on 11 May 2001 and is headquartered in Haifa, Israel.
Heska Corporation produces, sells and sells veterinary diagnostic and specialty health care products for dogs and cats in the United States, Canada, Europe and internationally. The Core Companion Animal Health segment of the company offers Element DC and DRI-CHEM 7,000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers for measuring the number of blood cells and platelets and the hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides imaging tools and services for veterinarians, such as digital radiography and ultrasound systems, and sells products for mobile digital radiography; Cloudbank, a web-based solution for image storage; ViewCloud, an image archive and communication system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of heartworm infections in dogs, and the treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shoots or drops. The Other vaccines, pharmaceuticals and products segment offers bovine vaccines, mainly under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and out-of-the-box services consisting of research, licensing, production, labeling and packaging. The company sells its products to veterinarians through a field organization and external distributors; and scholarships, print ads and other distribution relationships. Heska Corporation has a partnership for product development and a license agreement with MBio Diagnostics, Inc. The company was formerly known as Paravax, Inc. and changed the name to Heska Corporation. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Receive news and reviews for Pluristem Therapeutics Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Pluristem Therapeutics and related companies with the FREE daily email newsletter from MarketBeat.com.